1. Home
  2. YSG vs IFRX Comparison

YSG vs IFRX Comparison

Compare YSG & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yatsen Holding Limited

YSG

Yatsen Holding Limited

HOLD

Current Price

$2.66

Market Cap

318.9M

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$2.22

Market Cap

303.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YSG
IFRX
Founded
2016
2007
Country
China
Germany
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
318.9M
303.4M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
YSG
IFRX
Price
$2.66
$2.22
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$6.25
AVG Volume (30 Days)
62.7K
960.7K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.08
N/A
Revenue Next Year
$9.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$0.80
52 Week High
$10.28
$2.95

Technical Indicators

Market Signals
Indicator
YSG
IFRX
Relative Strength Index (RSI) 24.11 55.74
Support Level $2.15 $0.87
Resistance Level $3.49 $2.57
Average True Range (ATR) 0.18 0.17
MACD -0.06 0.00
Stochastic Oscillator 4.29 42.42

Price Performance

Historical Comparison
YSG
IFRX

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: